Loading
Nanoparticles / COVID-19 Vaccines / Mrna Vaccines · Journal article
Biomaterials · July 7, 2026
Encouraging direction, but not yet definitive.
This preclinical study describes a peptide-based nanocomplex for mRNA delivery that localizes to lymph nodes, sustains antigen expression for 7 days (versus 48 hours for lipid nanoparticles), and generates comparable neutralizing antibody titers with superior CD8+ T cell responses in immunized mice. The system showed no toxicity at doses up to 200 times the therapeutic dose in daily injections for 14 days, but remains an unvalidated proof-of-concept in a single animal model with no human data.
Preclinical in vivo comparative study (mouse model). BALB/c mice immunized with SARS-CoV-2 spike mRNA; no exclusion criteria stated. Intervention: Peptide-nanocomplex comprising RNA-binding peptide, l-polyglutamic acid, and APC-targeting cell-penetrating peptide with 7-mer immune cell-binding motif, formulated for lymph node targeting and mRNA delivery. Compared with: Lipid nanoparticles (LNPs). Not stated.
Peptide-nanocomplex formed stable particles under 200 nm mRNA expression sustained up to 7 days in vivo with peptide-nanocomplex versus 48 hours with LNPs Neutralizing antibody titers comparable to LNPs in SARS-CoV-2 spike mRNA-immunized mice
Preclinical mouse model only; no human immunogenicity or safety data Long-term safety and immunogenicity beyond two weeks not assessed; clinical translational path not defined
This work demonstrates proof-of-concept for peptide-based mRNA delivery with lymph node targeting and improved expression kinetics in mice; substantial translational development and human studies would be required before clinical application. The superior CD8+ response warrants further investigation but is not yet clinically validated.
Preclinical mouse study demonstrates a novel peptide-nanocomplex delivery system with improved lymph node targeting and prolonged antigen expression compared to lipid nanoparticles, with comparable neutralizing antibody responses and superior CD8+ T cell responses, but lacks human data and clinical validation.
As stated by the source record.
Quoted from the source exactly as published.
This work demonstrates proof-of-concept for peptide-based mRNA delivery with lymph node targeting and improved expression kinetics in mice; substantial translational development and human studies would be required before clinical application. The superior CD8+ response warrants further investigation but is not yet clinically validated.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Messenger RNA (mRNA) vaccines require efficient delivery systems to reach antigen-presenting cells (APCs). Lipid nanoparticles (LNPs) are a standard delivery carrier. However, LNPs often accumulate in the liver and exhibit transient protein expression. These limitations can restrict their safety and immunogenic potential. Here, we developed a modular, peptide-based nanocomplex to overcome the current limitations. The system comprises three functional peptides: an RNA-binding peptide (RBP) for condensation, l-polyglutamic acid (PGA) for charge modulation, and an APC-targeting cell-penetrating peptide (A-CPP). This A-CPP features a newly discovered 7-mer immune cell-binding motif identified in this study. We optimized the physicochemical properties by systematically fine-tuning the ratios of these peptide modules. The optimized nanocomplex formed stable particles under 200 nm. Unlike LNPs, which showed significant liver accumulation, the peptide-nanocomplexes remained localized at the injection site and effectively drained to the lymph nodes. Furthermore, the peptide-nanocomplex retained mRNA expression for up to 7 days in vivo, whereas LNP-mediated expression diminished within 48 h. In mice immunized with SARS-CoV-2 spike mRNA, this prolonged antigen exposure elicited robust neutralizing antibody titers comparable to LNPs. Notably, the peptide-nanocomplex induced significantly higher CD8+ T cell responses than LNPs. Moreover, the peptide-nanocomplex demonstrated an excellent safety profile in vivo with no toxicity observed even after daily injections for two weeks at doses up to 200 times higher. This study establishes a data-driven fine-tuning strategy for peptide-based mRNA delivery. The resulting peptide-nanocomplex offers a safer, lymph node-targeted, and longer-lasting efficacy alternative to lipid-based carriers for next-generation vaccines.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.